S&P 500
7,633.20
+0.31%
Dow Jones
53,893.00
+1.14%
Nasdaq 100
29,106.20
+0.99%
Russell 2000
2,995.41
+0.37%
FTSE 100
10,904.40
+0.20%
Nikkei 225
64,309.90
+1.28%
Cencora

Cencora (COR) Q3 2026 Earnings

Reported Aug 5, 2026 at 6:32 AM ET · SEC Source

Q3 26 EPS

$4.48

Q3 26 Revenue

$84.75B

vs S&P Since Q3 26

+3.5%

BEATING MARKET

COR +3.9% vs S&P +0.5%

Market Reaction

Did COR Beat Earnings? Q3 2026 Results

Cencora posted a strong fiscal third quarter for 2026, with adjusted diluted EPS of $4.48 climbing 12.0% year-over-year and revenue reaching $84.75 billion, up 5.1%, extending the company's streak of beating consensus EPS estimates to five consecutiv… Read more Cencora posted a strong fiscal third quarter for 2026, with adjusted diluted EPS of $4.48 climbing 12.0% year-over-year and revenue reaching $84.75 billion, up 5.1%, extending the company's streak of beating consensus EPS estimates to five consecutive quarters. The dominant force behind the results was the February 2026 acquisition of OneOncology, which meaningfully expanded U.S. Healthcare Solutions gross profit margins to 3.17% from 2.54% and powered segment operating income up 15.9% to $966.18 million, even as it pushed net interest expense 72.0% higher to $140.71 million given the $4.50 billion in debt raised to finance the deal. Beyond oncology, continued strength in specialty pharmaceutical distribution, rising GLP-1 sales, and solid international growth, with European distribution and global specialty logistics lifting international operating income 20.8%, reinforced the breadth of the company's pharmaceutical-centric strategy. Management nudged full-year adjusted diluted EPS guidance higher to $17.75 to $17.95, while targeting 4% to 6% revenue growth and 13% to 14% adjusted operating income growth, signaling confidence that specialty expansion and oncology integration will sustain momentum through fiscal year-end.

Key Takeaways

  • • Overall market growth driven by unit volume growth including increased sales of specialty products to health systems and physician practices
  • • Increased sales of GLP-1 products for diabetes and/or weight loss
  • • February 2026 acquisition of OneOncology driving U.S. Healthcare Solutions gross profit margin expansion
  • • Growth in European distribution and global specialty logistics businesses
  • • LIFO credit of $94.3 million in Q3 2026 versus $52.1 million in Q3 2025
  • • $102.0 million reduction of opioid liability from dismissed litigation

COR Forward Guidance & Outlook

Cencora raised its fiscal year 2026 adjusted diluted EPS guidance to a range of $17.75 to $17.95, up from $17.70 to $17.90 previously. Full-year revenue is expected to grow 4% to 6% (from fiscal 2025 actual of $321.3 billion). Adjusted operating income is expected to grow 13% to 14%. U.S. Healthcare Solutions segment revenue is guided to grow 4% to 6%, with adjusted operating income growth of 14.5% to 15.5%. International Healthcare Solutions revenue is expected to grow approximately 8%, with adjusted operating income growing approximately 9%. Other segment revenue is guided to grow approximately 6%, with adjusted operating income growing approximately 10%. Net interest expense is expected to be approximately $490 million. Adjusted effective tax rate is expected to be approximately 20%. Diluted weighted average shares outstanding are expected to be approximately 194 million. Adjusted free cash flow is expected to be approximately $3.0 billion, with capital expenditures of approximately $900 million.

24/7 Wall St

COR YoY Financials

Q3 2026 vs Q3 2025, source: SEC Filings

24/7 Wall St

COR Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q3 26

“Our third quarter results reflect the power of our pharmaceutical-centric strategy and the continued execution of our team members. Our strong performance and confidence in our outlook enabled us to raise our fiscal 2026 guidance, underscoring the value we deliver for our stakeholders.”

— Robert P. Mauch, Q3 2026 Earnings Press Release

Back to COR Stock Page